GLP-1 Weight Loss for Insulin Resistance and Metabolic Health Many patients interested in GLP-1 therapy also struggle with insulin resistance, prediabetes, type 2 diabetes risk, abdominal weight gain, cravings, fatigue after meals, or difficulty losing weight despite eating less
Source: Polaris Market Research Analysis Industry Developments February 2025: Biocon launched its GLP-1 peptide liraglutide in the UK under two brand names: Liraglutide Biocon (for diabetes, similar to Victoza) and Biolide (for chronic weight management, similar to Saxenda)
Thyroid Cancer: As with other GLP-1 medications, animal studies have shown a theoretical risk of thyroid tumours
They are exploring whether the two systems are linked or separate
The ingredients havent been studied in these populations, so its best to wait
It is the dose that supports meaningful progress while allowing the patient to eat, hydrate, function, preserve muscle, and maintain follow-up